CT059
Relapsed/Refractory Multiple Myeloma
Key Facts
About CARsgen Therapeutics
CARsgen Therapeutics is a clinical-stage biopharma with a mission to develop and commercialize innovative cell therapies for cancer, aiming to make cancer curable. The company has established itself as a notable player in the challenging field of solid tumor CAR-T therapy, with its lead asset CT041 (targeting Claudin18.2) achieving key regulatory designations in both China and the U.S. Its strategy leverages a fully integrated platform spanning discovery to manufacturing, with a dual geographic footprint in Houston, USA, and Shanghai, China, to drive global development.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Aplidin (plitidepsin) | PharmaMar | Approved (Conditional - AU) |
| TECVAYLI + DARZALEX FASPRO | Johnson and Johnson Innovative Medicine | Approved |
| Linvoseltamab | Regeneron | Phase 3 |
| Blenrep (belantamab mafodotin) | GSK | Phase III |
| CAR T-Cell Therapy Program | Dr. Reddy's Laboratories | Development |
| HDP-101 | Heidelberg Pharma | Phase I/IIa |
| inobrodib + Pd (InoPd) | CellCentric | Phase 1/2 |
| CT053 | CARsgen Therapeutics | Phase Ib/II |
| P-BCMA-ALLO1 | Poseida Therapeutics | Phase 1 |
| P-BCMA-101 | Poseida Therapeutics | Phase 1/2 |
| ABBV-383 | AbbVie | Phase 1 |
| bri-cel (BAY 2413334) | Bayer | Phase I |